By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Infinity Pharmaceuticals Inc. 

780 Memorial Drive

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-453-1000 Fax: 617-453-1001

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.

Small molecule discovery and development capabilities
Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.

Strategic alliances
Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.

Business and scientific expertise
The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.

Culture of Citizen-Ownership
Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.

Key Statistics

Ownership: Public

Web Site: Infinity Pharmaceuticals Inc.
Employees: 180
Symbol: INFI



Company News
Infinity Pharmaceuticals Inc. (INFI) Reports Phase 1 Data Showing Clinical Activity Of Duvelisib In Treatment-Naïve Patients With Chronic Lymphocytic Leukemia 6/1/2015 11:35:32 AM
Infinity Pharmaceuticals Inc. (INFI) To Participate In Three Investor Conferences In June 5/27/2015 11:27:56 AM
Infinity Pharmaceuticals Inc. (INFI) Reports Preclinical Data For Duvelisib Demonstrating Synergy With Standard-Of-Care Therapies And Emerging Agents In Development For The Treatment Of Hematologic Malignancies 5/26/2015 8:34:59 AM
Infinity Pharmaceuticals Inc. (INFI) Announces New Data For Duvelisib To Be Presented At The 2015 ASCO Annual Meeting 5/14/2015 12:22:32 PM
Infinity Pharmaceuticals Inc. (INFI) Reports First Quarter 2015 Financial Results And Recent Corporate Developments 5/6/2015 12:16:35 PM
Infinity Pharmaceuticals Inc. (INFI) To Participate In Three Conferences In May 4/30/2015 12:43:43 PM
Infinity Pharmaceuticals Inc. (INFI) Announces The Date Of Its First Quarter 2015 Financial Results Conference Call And Webcast 4/22/2015 8:38:50 AM
Infinity Pharmaceuticals Inc. (INFI) Reports Preclinical Data For Duvelisib In Combination With Venetoclax At The 2015 AACR Annual Meeting 4/20/2015 1:14:46 PM
Infinity Pharmaceuticals Inc. (INFI) Augments Executive Leadership Team, Appointing Chief Commercial Officer And General Counsel 4/14/2015 10:45:20 AM
Infinity Pharmaceuticals Inc. (INFI) Shells Out $52.5M to Purchase Cancer Drug Royalties From Takeda (TKPYY) 3/31/2015 9:14:25 AM